Truffle Capital, an investor in BioMedical Diagnostics, is a European private equity firm originally set up for investments in spin-offs from companies active in the IT, Energy, and Life Sciences sectors.
-
BMD (BioMedical Diagnostics), a spin-off from Abbott Diagnostic and Luminex, is an in vitro diagnostic company focused on auto-immunity and infectious diseases, with 2006 revenues of €15.7 million.
-
Bmd’s revenues are derived from home-made products (25%) and distribution OEM products (75%) with direct sales in France and a network of distributors in Europe, Australia, and Latin America. Bmd has established a solid presence in France with #1 ranking and 40% market share in autoimmunity diseases.
-
BMD is considering an IPO in late 2007.
-
Truffle Capital board member: Philippe Pouletty, M.D.